Program
EB-DUO-CAR-NK-CEA/GCC
Also written as “EB-DUO-CAR-NK-CEA/GCC (IV)”.
Its studies are mostly in Colorectal Neoplasms · Colonic Neoplasms, led by Beijing Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Biotech | 22 open or running | phase 2since Feb 14, 2026 | Feb 14, 2026 | Mar 14, 2027phase 2 · NCT07589517 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 14, 2026First study: phase 2 study in Colonic NeoplasmsFirst studyNCT07462650 · 48 planned · China
- May 10, 2026Phase 2 study in Colorectal NeoplasmsNCT07589517 · 48 planned · China
Ahead
- Mar 14, 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07589517
- Dec 21, 2027Primary completion: phase 2 study in Colonic NeoplasmsNCT07462650
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07589517Colorectal Neoplasms · China | 2 | Recruiting | Mar 14, 2027 | 48 |
| NCT07462650Colonic Neoplasms · China | 2 | Recruiting | Dec 21, 2027 | 48 |
How it is read
Names in the registry
- “EB-DUO-CAR-NK-CEA/GCC”, 1 entry
- “EB-DUO-CAR-NK-CEA/GCC (IV)”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Colonic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.